Trial Profile
An Open-label, Long Term Extension Study for Treatment of Pulmonary Arterial Hypertension in Paediatric Patients Aged 8 Years up to 18 Years Who Have Participated in AMB112529 and in Whom Continued Treatment With Ambrisentan is Desired
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Ambrisentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 23 Sep 2023 The trial has been completed in Germany, Spain, Italy, according to European Clinical Trials Database.
- 04 Nov 2022 Status changed from active, no longer recruiting to completed.
- 23 Oct 2022 This trial has been completed in Hungary, according to European Clinical Trials Database.